Market Access
Our analyses and commentary on market access, reimbursement and pharmacoeconomics
The market reached TRY 430.8 billion in 2025; roughly 80% of growth came from price and only 2 points from new products. The full picture with import-domestic, originator-generic and biotech splits.
Read
According to the 2026 Rare Diseases Workshop report, the average time to correct diagnosis in Türkiye is 6-7 years with more than 8 physician visits. The clinical and cost price of delay...
Read
The Regulation on Promotional Activities entered into force on 1 January 2025. Expanded scope, digital rules and stepped sanctions are now on every company's agenda.
Read
While drug reimbursement runs under SUT, hospital services are priced through the Public Health Services Price Tariff. Three 2026 revisions, health-tourism floor prices and USHAŞ coefficients...
Read
Six separate SUT amendment decrees have been published since December 2025. What does the changing picture — from SMA criteria to EK-4/C prices — mean for companies?
Read
In an era of USD 4.4 million single-dose therapies, the Summit 2026 report exposes the question gap between Europe and Türkiye: how do you build a sustainable payment architecture for ultra-rare diseases?
Read
TİTCK, the SGK HTA unit and TÜSEB form a three-legged ecosystem with limited mandatory power. As assessment standards rise, companies fill the evidence gap.
Read
Under Decree No. 73 the euro rate was raised 16.9% in December 2025 and stepped up from TRY 25.33 to 29.11 during 2026. Pricing strategy is now managed on an FX calendar.
Read
Institutionalised in 2016 and updated in 2023, alternative reimbursement models now cover NPP products too. How to build the most flexible access tool for innovative medicines?
Read